Collectively, the Division is supported by over $4 million in annual research funding, which is aimed at improving the lives of and outcomes for blood cancer patients.
Allogeneic Transplantation Trials
Leukemia Trials *AML & ALL*
Lymphoma Trials *B- and T-cell*
Multiple Myeloma Trials
Myelodysplastic Syndrome Trials *MDS & CMML*
Myeloproliferative Neoplasms Trials *MPN: ET, MF, PV*
Non-Cancerous Blood Disorder Trials
Quality of Life Studies
Tissue Bank Studies
Colorado's Only NCI Designated Cancer Center
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available
to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.
Investigators in the Division of Hematology’s Blood Cancer Program are actively engaged in multiple research activities aimed at improving outcomes for patients with blood cancers and related disorders. These studies are wide-ranging and involve extensive collaboration between laboratory scientists and physicians. Our work is funded by the National Cancer Institute (NCI), the American Cancer Society (ACS), the Leukemia and Lymphoma Society (LLS), and numerous other foundations and industry sources. A key strength of our research group is its highly collaborative and cross-disciplinary nature, which provides an ideal environment in which to develop new therapies. The Hematology Clinical Trials Unit (HCTU) plays an integral role in conducting the clinical research components of the division and have made bringing bench to bedside research a huge divisional success. The HCTU is comprised of 32 employees, and their dedication and investment each day is seen and felt by all patients that have and will participate in a clinical trial.